T CELL RECEPTORS TARGETING THE HIGHLY PREVALENT KRAS G12V MUTATION ON HLA-A11:01 IN LUNG CANCER

The present disclosure is directed to recombinant T-cell Receptors (TCRs) that binds Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) protein comprising a G12V mutation presented on a human leucocyte antigen-A (HLA-A)*11:01, polynucleotides encoding such TCRs, engineered T-cells comprising such TCR...

Full description

Saved in:
Bibliographic Details
Main Authors LIZEE, Gregory A, REUBEN, Alexandre, HEYMACH, John Victor, ZHANG, Minying, JIANG, Peixin
Format Patent
LanguageEnglish
French
Published 15.08.2024
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present disclosure is directed to recombinant T-cell Receptors (TCRs) that binds Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) protein comprising a G12V mutation presented on a human leucocyte antigen-A (HLA-A)*11:01, polynucleotides encoding such TCRs, engineered T-cells comprising such TCRs, and methods of using the same. La présente invention concerne des récepteurs de lymphocytes T recombinants (TCR) qui se lient à une protéine homologue d'oncogène viral de sarcome de rat de Kirsten (KRAS) comprenant une mutation G12V présentée sur un antigène leucocytaire humain-A (HLA-A)*11:01, des polynucléotides codant pour de tels TCR, des lymphocytes T modifiés comprenant de tels TCR, et des procédés d'utilisation de ceux-ci.
Bibliography:Application Number: WO2024US10346